$591 | SAVE $104 | Single User
$2423 | SAVE $427 | Site License
$4803 | SAVE $847 | Global License

Value-driven Pharma: Integrating health outcomes across the product lifecycle

Value-driven Pharma: Integrating health outcomes across the product lifecycle
[Lowest Price Guaranteed: $591]

Published by FirstWord Pharma: 24 Feb 2014 | 101 | In Stock
Related Topics: Pricing



Two recessions in a decade, financial austerity, and unprecedented pressure to prove product value to all stakeholders. There is no question that the pharma game has changed in the new “Outcomes Era”, in which health economics and outcomes research (HEOR) departments have moved from the background to the driver’s seat.

But how is pharma handling the new pressures to develop products that not only deliver blockbuster revenue but real world health outcomes, too? Are pharma companies truly integrating health outcome values into product development or merely paying lip-service?

In a rare and comprehensive insight into thriving in the "Outcomes Era", Value-driven Pharma: Integrating health outcomes across the product lifecycle tackles the issues that have not been publicly addressed in full. The report first looks at the current relationship between pharma and stakeholders, against a backdrop of economic recession. It also examines the disconnect between pharmaメs pledge to build value-driven products whilst failing to instil health outcome values at the critical early development stages. Filled with invaluable information from key industry insiders, the dossier is essential reading for R&D or medical directors, CEOs, heads of managed markets and anyone else interested in steering towards success in a tumultuous economic age.

Puchase Reasons

Key Benefits

Attitudes toward drug reimbursement have been shaped by economics. In Value-driven Pharma: Integrating health outcomes across the product lifecycle, you will:

  • Understand the importance of endorsing a comprehensive approach to health outcomes from the earliest stages of product development

  • Gain insight into devising strategies that incorporate health outcomes initiatives from drug discovery to market rollout

  • Understand how to approach payers on a case-by-case basis, tailor data and prioritise transparency

  • Be able to develop strategies that align health outcome initiatives across a number of teams, from managed markets professionals to health outcome liaisons

  • Filled with compelling and important insights into an evolving market, the report offers:

  • Detailed examination of the integration of health outcomes initiatives into drug discovery and early stage development

  • Advice on how to tailor health outcomes data to specific payers

  • Insight on best practices for enhancing relationships while overcoming payer skepticism of the industry

  • Up-to-date comparison of companies’ efforts in launching health outcomes initiatives, as well as an analysis of their practices

  • A case study detailing the Economic Perspectives Implemented in Clinical Development (EPIC) from UCB Pharma.

  • Key Questions Answered

  • How do pharma companies compare in relation to health outcome initiatives?

  • Is there a demonstrable benefit to starting health outcomes research in early stages, as opposed to post-launch?

  • What can companies do to integrate health outcomes into R&D, in order to ensure real-world value?

  • How can companies with a silo culture integrate aligned health outcomes into a matrix?

  • How can data be tailored and leveraged with payers?

  • Highlights

    Key quotes

    “The need to be innovative in terms of bringing added value to the customer is clear. It was always there, but there was a certain tolerance, shall we say, of me-toos and second-, third- and fourth-in-class for any given indication. Now, that level of tolerance is definitely gone.” Jonathan Plumb, Head, Market Access & Pricing, CNS at UCB Pharma.

    “In this day and age it is all about outcomes. I don't talk about value because value has become a dirty word — overused and under-delivered. Outcomes, by contrast, is a word that speaks for itself.” Ashok Bhaseen, Vice President Marketing and Sales at Pediapharm and President of Thyroid Federation International.

    “Value is the mantra right now. We have to demonstrate value in three different ways: Economic value, clinical value and humanistic value — the value from the perspective of payers, physicians and patients.” Siva Narayanan, Senior Vice President, Evidence Generation, Value and Access at Ipsos.

    As the economic fallout of two recessions in a decade impacts pharma, the industry is focusing its attention on health outcomes initiatives. In this report, you will discover:

  • The value of starting health outcomes research early—very early—and not after a product is launched and in need of ‘dressing up.’

  • The importance of innovation in both implementing and integrating health outcomes initiatives

  • The most current industry data, including a case study of the Economic Perspectives Implemented in Clinical Development (EPIC) initiative from UCB Pharma.

  • Why it’s important to overcome a silo mentality and work within a matrix approach to ensure alignment of health outcomes initiatives.
  • Table of Contents
    for Value-driven Pharma: Integrating health outcomes across the product lifecycle

    • 1. Executive Summary

      2. Part One: The Outcomes Era

      2.1.An uneven state of play

      2.2.Common hurdles, hiccups, frustrations

      2.3.Best practices

      3.Part Two: Embracing outcomes from the start

      3.1.Narrowing the list of potential indications

      3.2.Early-stage stakeholder engagement

      3.3.Early economic evaluation

      3.4.Further targeting via personalised medicine

      3.5.An emerging industry norm

      4.Part Three: Health outcomes and clinical trials

      4.1.The clinical trial conundrum

      4.2.Step One: Survey the landscape and start early

      4.2.1.Interviewing payers

      4.3.Step Two: Piece together a hypothetical profile

      4.4.Step Three: Craft and test a strateg

      5.Part Four: A case study in systematically integrating outcomes

      and the payer perspective from early on into drug discovery

      and development

      5.1.Business Objectives

      5.2.Set up and organization

      5.3.EPIC workshops and ambassadors

      5.4.TA and compound-level strategy sessions


      6.Part Five: Taking outcomes to market

      6.1.One size fits one

      6.2.Transparency is paramount

      6.3.Go big

      6.4.Prove it with their own data

      6.5.Take risks and be innovative

      7.Part Six: The alignment imperative

      7.1.Implementing a matrix

      7.2.The need for a strong leader

      7.3.Mastering handoffs

      7.4.Third-party integration

      8.Expert contributors

    Additional Details


    FirstWord Pharma

    Publisher Information


    101 |

    Number of Pages


    Report Format


    FirstWord Pharma Reports

    Related Reports

    TitleDate PublishedPrice fromMore Details
    SAVE 15% today! Big Data in Pharma Marketing
    IntroductionBig data - the huge volume of digital data generated worldwide - continues to grow expon...
    01 Jan 2013 by FirstWord Pharma USD $591 (normally
    USD $695)
    More Info
    SAVE 15% today! The Rise of Health Outcome Liaison Teams
    IntroductionWhen it comes to market access, the payers hold the cards. However, in recent years, pha...
    01 Nov 2012 by FirstWord Pharma USD $591 (normally
    USD $695)
    More Info
    SAVE 15% today! Social and Mobile Pharma - the State of the Digital Landscape
    IntroductionTightly-regulated and conservative in outlook, the pharmaceutical industry has largely b...
    01 Nov 2012 by FirstWord Pharma USD $591 (normally
    USD $695)
    More Info
    SAVE 15% today! Pharma and Payers – Building Better Relationships
    IntroductionChanges in the healthcare landscape have put payers (public and private) under mounting ...
    01 Sep 2012 by FirstWord Pharma USD $591 (normally
    USD $695)
    More Info
    SAVE 15% today! Pharma Reputations: Managing Perceptions
    IntroductionPharma is no stranger to the idea of nurturing and defending corporate reputations. But...
    01 Aug 2012 by FirstWord Pharma USD $548 (normally
    USD $645)
    More Info
    SAVE 15% today! Pharma's Future Role in CME
    IntroductionOver the last 10 years, every aspect of continuing medical education (CME) has endured m...
    01 Aug 2012 by FirstWord Pharma USD $591 (normally
    USD $695)
    More Info
    SAVE 15% today! Pharma sales force shape, size and structure — where next?
    IntroductionRetarget your sales force with new resourcesSales force management now plays a critical ...
    01 Jul 2012 by FirstWord Pharma USD $591 (normally
    USD $695)
    More Info
    SAVE 15% today! Inside China’s Healthcare Reforms: Opportunities for Multinational Pharma
    IntroductionIn 2009, China’s government announced plans to invest RMB1.13 trillion (0 billion) in...
    01 Jun 2012 by FirstWord Pharma USD $846 (normally
    USD $995)
    More Info
    SAVE 15% today! Meeting KOL Needs: What Pharma Needs to Know
    IntroductionThe role of the Key Opinion Leader (KOL) has changed over the past 30 years. And it's ab...
    01 Feb 2012 by FirstWord Pharma USD $1,228 (normally
    USD $1,445)
    More Info
    SAVE 15% today! Academic Detailing: Pharma Fights Back
    IntroductionEver since it was introduced three decades ago, academic detailing—which now increasingl...
    01 Jan 2012 by FirstWord Pharma USD $633 (normally
    USD $745)
    More Info

    This report is published by FirstWord Pharma

    Download Free Report Summary PDF

    Value-driven Pharma: Integrating health outcomes across the product lifecycle | Download PDF Summary

    Download our FREE report summary PDF. It contains all the information on these web pages, plus a Proforma Invoice request form, should you need it to satisfy your company's internal order procedures.

    Ordering Information

    Orders are processed immediately and you will be notified of the despatch date on confirmation of your order.

    Accepted Card Types


    Buy now using our secure payment system.

    We Stock...